Azithromycin in DuraSite for the treatment of blepharitis

Jodi Luchs, Jodi Luchs

Abstract

Blepharitis is a common inflammatory disease of the eyelid. Posterior blepharitis affects the posterior lamella of the eyelid and involves inflammation of the meibomian glands, whereas anterior blepharitis affects the anterior lamella of the eyelid and the eyelashes; either version can be inflammatory or infectious in nature. Each of these conditions can incite or propagate the other; anterior blepharitis, if not treated, can lead to meibomian gland disease, and vice versa. Blepharitis is typically chronic, and can be associated with a variety of systemic diseases such as dermatitis, as well as ocular diseases such as dry eye, conjunctivitis, or keratitis. The standard treatment regimen historically consists of lid hygiene with warm compresses and eyelid scrubs, although these treatment modalities may have limited efficacy for many patients, especially those with more severe disease. Adjunctive treatment includes systemic and topical antibiotics, topical corticosteroids, and tear replacement therapy. Topical antibiotics are recommended to decrease the bacterial load, and topical corticosteroids may help in cases of severe inflammation. Azithromycin ophthalmic solution 1% in DuraSite((R)) (AzaSite((R)); Inspire Pharmaceuticals, Durham, North Carolina, USA) has been proposed as a novel treatment for posterior blepharitis, based on its well-known anti-infective profile, its anti-inflammatory properties, its excellent tissue penetration, and its regulatory approval for the treatment of bacterial conjunctivitis. This review focuses on an off-label indication for topical azithromycin 1% in DuraSite for the treatment of blepharitis.

Keywords: lid margin disease; meibomian gland disease.

Figures

Figure 1
Figure 1
Effects of topical azithromycin in combination with warm compresses, compared with warm compress-only group on lid redness. Note: The clinical signs were rated by the investigator as 0 = normal, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.
Figure 2
Figure 2
Effects of topical azithromycin in combination with warm compresses, compared with warm compress-only group on meibomian gland plugging. Note: The clinical signs were rated by the investigator as 0 = normal, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.
Figure 3
Figure 3
Effects of topical azithromycin in combination with warm compresses, compared with warm compress-only group on quality of meibomian gland secretion. Note: The clinical signs were rated by the investigator as 0 = normal, 1 = mild, 2 = moderate, 3 = severe, and 4 = obstructed.

References

    1. American Optometric Association. Optometric clinical practice guideline: care of the patient with ocular surface disorders. 2002. Available from: Accessed Jan 14, 2010.
    1. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol. 2008;43(2):170–179.
    1. Smith RE, Flowers CW. Chronic blepharitis: a review. CLAO J. 1995;21(3):200–207.
    1. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1:107–126.
    1. American Academy of Ophthalmology. Preferred practice patterns: blepharitis. 2008. Available from: Accessed Jan 20, 2010.
    1. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009;7(Suppl 2):S1–S14.
    1. Campbell Alliance Group. Patterns of practice and prevalence rates for lid margin disease. 2008 July–Aug.
    1. Venturino G, Bricola G, Bagnis A, Traverso CE.Chronic blepharitis: treatment patterns and prevalence Invest Ophthalmol Vis Sci. 200344[E-Abstract 774].
    1. Hom MM, Martinson JR, Knapp LL, Paugh JR. Prevalence of meibomian gland dysfunction. Optom Vis Sci. 1990;67:710–712.
    1. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis) Trans Am Ophthalmol Soc. 2008;106:336–356.
    1. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin, and clarithromycin. J Antimicrob Chemother. 1998;41(Suppl B):47–50.
    1. Jacot JL, Jacot TA, Sheppard JD, et al. Evaluation of MMP 2/9 modulation by AzaSite and DuraSite in human corneal epithelial cells and bovine corneal endothelial cells in vitro. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2008. Apr 28,
    1. Donaldson KE, Karp CL, Dunbar MT. Evaluation and treatment of children with ocular rosacea. Cornea. 2007;26(1):42–46.
    1. Pecosky DA, Robinson JR. Bioadhesive polymers and drug delivery. In: Tarcha PJ, editor. Polymers for Controlled Drug Delivery. Boca Raton, FL: CRC Publications; 1991. pp. 100–122.
    1. Lux A, Maier S, Dinslage S, et al. A comparative bioavailability study of three conventional eye drops versus a single lyophilisate. Br J Ophthamol. 2003;87(4):436–440.
    1. Protzko E, Bowman L, Abelson M, Shapiro A, for AzaSite Clinical Study Group Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007;48(8):3425–3429.
    1. Akpek EK, Vittitow J, Verhoeven RS, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009;25(5):433–439.
    1. Friedlander MH, Protzko E. Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy. Clin Ophthalmol. 2007;1(1):3–10.
    1. Kowalski RP, Yatea KA, Romanowski EG, Karenchak LM, Mah FS, Gordon YJ. An ophthalmologist’s guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology. 2005;112:1987–1991.
    1. Park SH, Lim JA, Choi JS, Kim KA, Joo CK. The resistance patters of normal ocular bacterial flora to 4 fluoroquinolone antibiotics. Cornea. 2009;28:68–72.
    1. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother. 1987;31(12):1939–1947.
    1. Pechere JC. Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity. Pathol Biol (Paris) 1995;43(6):483–487.
    1. Brown BA, Wallace RJ, Jr, Onyi GO, de Rosas V, Wallace RJ., III Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother. 1992;36(1):180–184.
    1. Torkildsen G, O’Brien TP. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. Clin Ther. 2008;30(11):2005–2014.
    1. AzaSite [package insert] Durham, NC: Inspire Pharmaceuticals; 2008.
    1. Abelson M, Protzko E, Shapiro A, Graces-Soldana A, Bowman L, for the 1% azithromycin in DuraSite Clinical Study Group A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. Clin Ophthalmol. 2007;1(2):177–182.
    1. Vigamox [package insert] Fort Worth, TX: Alcon Laboratories, Inc; 2008.
    1. Zymar [package insert] Irvine, CA: Allergan, Inc; 2004.
    1. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500–505.
    1. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exper Ther. 2000;292(1):156–163.
    1. Amsden GW.Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? Review J Antimicrob Chemother 20055510–21.Epub 2004 Dec 8.
    1. Shinkai M, Rubin BK. Macrolides and airway inflammation in children. Review. Paediatr Respir Rev. 2005;6:227–235.
    1. Zhou N, Ma P, Li D-Q, Pflugfelder SC. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2009. May 3–7, Azithromycin suppresses pro-inflammatory mediators stimulated by a TLR2 ligand zymosan in human corneal epithelial cells.
    1. Sadrai Z, Hajrasouliha AR, Chauhan SK, Saban DR, Dastjerdi MH, Dana R. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2009. Effect of topical azithromycin on innate immune responses in experimental keratitis.
    1. Stewart WC, Crean CS, Zink RC, Haque R, Hwang DG. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2009. May 3–7, Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens.
    1. Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008;25(9):858–870.
    1. Trattler WB, Kuhn KL, Haque R, Zink RC, Sall KN, Luchs J. San Francisco, CA: American Society of Cataract and Refractive Surgery; 2009. Apr 3–8, Topical azithromycin improves blepharitis signs and symptoms.
    1. Touhey D, Shapiro A, Torkildsen G, et al. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2009. May 3–7, Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of chronic blepharitis patients.
    1. Haque RM, Torkildsen GL, Brubaker K, et al. Multi-center, open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. In press.
    1. Foulks GN, Borchman D, Yappert M. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2009. May 3–7, Modification of meibomian gland lipids by topical azithromycin.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner